Company Description
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need.
The company’s proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unmet medical needs and pain relief for knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery.
The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.
Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
| Country | Canada |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | James Helliwell |
Contact Details
Address: 2067 Cadboro Bay Road, Suite 201 Victoria, BC V8R 5G4 Canada | |
| Phone | 250-590-3968 |
| Website | eupraxiapharma.com |
Stock Details
| Ticker Symbol | EPRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001581178 |
| ISIN Number | CA29842P1053 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James A. Helliwell FRCPC, M.D. | Chief Executive Officer and Director |
| Dr. Amanda Malone Ph.D. | Chief Scientific Officer and Chief Operating Officer |
| Paul Anthony Brennan B.Sc., M.Sc. | Chief Business Officer |
| Dr. Mark M. Kowalski M.D., Ph.D. | Chief Medical Officer |
| Alexander John Rothwell Eng., M.B.A. | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 2, 2025 | 6-K | Report of foreign issuer |
| May 7, 2025 | 6-K | Report of foreign issuer |
| May 6, 2025 | 6-K | Report of foreign issuer |
| May 5, 2025 | 6-K | Report of foreign issuer |
| Apr 24, 2025 | 6-K | Report of foreign issuer |
| Mar 21, 2025 | 6-K | Report of foreign issuer |
| Mar 20, 2025 | 40-F | Filing |
| Feb 25, 2025 | 6-K | Report of foreign issuer |
| Feb 18, 2025 | 6-K | Report of foreign issuer |
| Nov 20, 2024 | 6-K | Report of foreign issuer |